FindTrial
Sign In

This is an observational trial planned to study the levels of biomarkers bio-ADM and penKid for shock/multiorgan failure in patients with sepsis (also known as blood poisoning).

Prospective, Observational Study of Novel Biomarkers bio-ADM & penKid for prediction of manifestation of Sepsis related Multiorgan Failure or Shock and to monitor Severity & Outcomes in Patients with Sepsis

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2023/01/048819
Enrollment
50
Registered
2023-01-09
Start date
Unknown
Completion date
Unknown
Last updated
2023-03-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: R579- Shock, unspecified

Interventions

None listed

Sponsors

Rivaara Labs Pvt. Ltd.
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Subjects with clinically suspected sepsis admitted in ICU 1. Above18 years of age 2. Expected ICU stay of more than 24 hrs

Exclusion criteria

Exclusion criteria: 1. Age below 18 years 2. Pregnant or lactating mothers 3. Terminal stage disease

Design outcomes

Primary

MeasureTime frame
Plasma levels of Biomarkers bio-ADM and penKid will be assessed to decide the need for vasopressors and therapy modification as appropriate.Timepoint: At time of admission, Day 3 and Day 7 or at admission, Day 2 and Day 5 (as deemed fit by the PI)—

Secondary

MeasureTime frame
All cause ICU mortality, length of ICU stay, need for Renal Replacement Therapy and mechanical ventilation.Timepoint: 07 Days—

Countries

India

Contacts

Public ContactDr Yatin Mehta

Medanta - The Medicity, Department of Critical Care and Anesthesia

yatin.mehta@medanta.org0124-4141414

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026